

Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}



>{{PANUMCODE}}

Verzenio

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155.** If you have questions regarding the prior authorization, please contact CVS Caremark at 1-866-814-5506. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: {{MEMFIRST}} {{MEMLAST}} **Date:** {{TODAY}}
Patient's ID: {{MEMBERID}} **Patient's Date of Birth:** {{MEMBERDOB}}
Physician's Name: {{PHYFIRST}} {{PHYLAST}}
Specialty: _____, **NPI#:** _____
Physician Office Telephone: {{PHYSICIANPHONE}} **Physician Office Fax:** {{PHYSICIANFAX}}
Request Initiated For: {{DRUGNAME}}

- What is the patient's diagnosis?
 Breast cancer
 Other _____
- What is the ICD-10 code? _____
- What is the clinical setting in which the requested medication will be used?
 Early disease
 Recurrent disease
 Advanced disease
 Metastatic disease
 Other _____
- Is this a request for continuation of therapy with the requested medication? *If Yes, skip to #7* Yes No
- What is the patient's hormone receptor (HR) status? **ACTION REQUIRED: Attach chart note(s) or test results of hormone receptor (HR) status.** HR-positive HR-negative Unknown
- What is the patient's human epidermal growth factor receptor 2 (HER2) status? **ACTION REQUIRED: Attach chart note(s) or test results of human epidermal growth factor receptor 2 (HER2) status.**
 HER2-positive HER2-negative Unknown *Skip to clinical setting section.*
- Is there evidence of unacceptable toxicity or disease progression on the current regimen? Yes No

Complete the following section based on the patient's clinical setting, if applicable.

Section A: Recurrent, Advanced, or Metastatic Breast Cancer

- Will the requested medication be given in any of the following regimens?
 As monotherapy
 In combination with fulvestrant, *no further questions.*
 In combination with an aromatase inhibitor (e.g., letrozole, anastrozole, exemestane), *no further questions.*
 Other _____

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Verzenio SGM - 4/2023.

CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081

Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com

Member Name: {{MEMFIRST}} {{MEMLAST}} **DOB:** {{MEMBERDOB}} **PA Number:** {{PANUMBER}}

9. Did the patient experience disease progression following endocrine therapy and prior chemotherapy in the metastatic setting? Yes No

Section B: Early Breast Cancer

Continuation

10. How many months has the patient received therapy with the requested medication? _____ months

Initial

11. Will the requested medication be used as adjuvant treatment? Yes No
12. Will the requested medication be given in combination with endocrine therapy (tamoxifen or an aromatase inhibitor [e.g., letrozole, anastrozole, exemestane])? Yes No Unknown
13. Does the patient have node positive disease?
 Yes, four or more positive lymph nodes, *no further questions.*
 Yes, one to three positive lymph nodes
 No
14. Does the patient have any of the following?
 Grade 3 disease
 Tumor size of 5 cm or greater
 None of the above

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Verzenio SGM - 4/2023.

CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081

Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com